Three-Drug Pancreatic Cancer Therapy Nears the Clinic, With Breakthrough and Retraction Shadow Side by Side

Pancreatic cancer is feared not only because it is often discovered too late, but also because it always seems able to find an escape route under drug pressure. A three-drug combination proposed by Mariano Barbacid’s team at the Spanish National Cancer Research Centre therefore once generated strong expectations: across multiple mouse models, the treatment did not merely delay tumors, but produced deep and durable regression of pancreatic ductal adenocarcinoma.

The strategy focuses its attack on pancreatic cancer’s most stubborn molecular network. According to summaries by research institutions and science media, the combination includes the KRAS inhibition-related drug daraxonrasib, the EGFR inhibitor afatinib, and SD-36, a protein degrader targeting STAT3. The logic is to suppress the tumor’s core driver, bypass signaling, and resistance mechanisms at the same time, preventing cancer cells from quickly rerouting after a single pathway is blocked.

CNIO originally said the therapy caused significant and durable tumor regression in three mouse models of pancreatic cancer, with no obvious toxicity observed; Live Science reported that after tumors disappeared completely in the study, no recurrence was seen for at least 200 days. EL PAÍS further noted that the complete and durable regression results involved 45 mice. If these figures can be independently reproduced, they are indeed enough to explain why plans for subsequent clinical trials came onto the table.

But this does not mean patients already have an available therapy. Mouse models can test mechanisms precisely, but they cannot fully represent the genetic diversity, immune environment, dose tolerability, and long-term side effects of human tumors. A three-drug combination also means toxicity assessment is more complex; in humans, whether suppressing cancer-cell signaling will also harm normal tissue function is one of the hardest thresholds to cross between preclinical and clinical development.

What makes this research even more sensitive is that the related PNAS paper was later retracted. CNIO’s news page retains an updated note saying the retraction was related to undeclared competing interests involving Vega Oncotargets; Cadena SER also reported that the controversy involved insufficient disclosure of financial interests in the company. This kind of retraction does not necessarily directly overturn the experimental results themselves, but it weakens the trust of readers, patients, and funders in the research narrative, and makes subsequent validation need to be even more transparent.

Therefore, the truly important next step is not to translate “mouse tumors disappeared” directly into “pancreatic cancer can be cured,” but to return the data to a reviewable position: which models were effective, which genetic backgrounds may not apply, how the three drugs are combined, how toxicity is monitored, and how conflicts of interest are fully disclosed. If clinical trials begin, the early goals should also be safety, dosage, and biomarker changes, rather than premature promises of efficacy.

Progress in pancreatic cancer treatment has been slow for many years, and every approach that can get close to the core cancer-driving mechanisms deserves serious attention. The scientific concept behind this three-drug therapy has weight, and the retraction also carries a warning signal; the coexistence of both is its most accurate position for now. For patients, hope needs to be preserved, but even more, it needs to be gradually supported by evidence.